Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News bluebird bio Inc. BLUEV


Primary Symbol: BLUE

bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.


Recent & Breaking News (NDAQ:BLUE)

bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program

Business Wire December 20, 2021

bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor

Business Wire December 17, 2021

New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM

Business Wire December 12, 2021

New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels

Business Wire December 11, 2021

bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions

Business Wire November 22, 2021

bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress

Business Wire November 5, 2021

bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row  

Business Wire November 5, 2021

bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

Business Wire November 4, 2021

bluebird bio Completes Planned Business Separation

Business Wire November 4, 2021

bluebird bio Sets Record Date and Distribution Date for Planned Business Separation

Business Wire October 18, 2021

bluebird bio Provides Update on Upcoming Planned Business Separation

Business Wire October 8, 2021

bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions

Business Wire September 21, 2021

2seventy bio Announces Upcoming Investor Events

Business Wire September 13, 2021

bluebird bio Secures $75 Million in Private Placement Equity Financing

Business Wire September 8, 2021

bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events

Business Wire September 7, 2021

BLUEBIRD BIO INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE

Business Wire August 13, 2021

bluebird bio Reports Second Quarter Financial Results and Provides Operational Update

Business Wire August 9, 2021

bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events

Business Wire August 5, 2021

bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 4, 2021

Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies

Business Wire July 28, 2021